Ambu's goals for the new 2021/2022 financial year are considerably more conservative than what the market had hoped for.
Prior to the medtech company's report, analysts had estimated a financial guidance with an organic growth of around 20 percent, but Ambu reports today that 2021/2022 will deliver organic growth between 15 and 19 percent, according to their guidelines.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.